Startseite Crystal structure of 4-bromobenzyl 2-(6-methoxy-naphthalen-2-yl)propanoate, C21H19BrO3
Artikel Open Access

Crystal structure of 4-bromobenzyl 2-(6-methoxy-naphthalen-2-yl)propanoate, C21H19BrO3

  • Xin-Ru Zhang ORCID logo , Da-Zhuan Lin und Li-Na Gao ORCID logo EMAIL logo
Veröffentlicht/Copyright: 2. September 2024

Abstract

C21H19BrO3, orthorhombic, P212121 (no. 19), a = 6.011(2) Å, b = 11.630(2) Å, c = 25.165(5) Å, V = 1759.3(7) Å3, Z = 4, Rgt (F) = 0.0163, wRref (F 2) = 0.0420, T = 100(2) K.

CCDC no.: 2375767

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.12 × 0.11 × 0.10 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 2.35 mm−1
Diffractometer, scan mode: Bruker APEX-II
θ max, completeness: 27.5°, >99 %
N(hkl)measured, N(hkl)unique, R int: 84,060, 4,020, 0.037
Criterion for I obs, N(hkl)gt: I obs > 2 σ(I obs), 3,879
N(param)refined: 228
Programs: Bruker, 1 Olex2, 2 SHELX 3
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
Br1 0.08234 (3) −0.15505 (2) 0.74872 (2) 0.02566 (6)
C1 0.2394 (3) −0.04140 (16) 0.70911 (7) 0.0182 (3)
C2 0.4405 (3) −0.06943 (16) 0.68613 (8) 0.0210 (4)
H2 0.498387 −0.145251 0.688661 0.025*
C3 0.5568 (3) 0.01614 (16) 0.65912 (8) 0.0203 (4)
H3 0.695523 −0.001965 0.643087 0.024*
C4 0.4741 (3) 0.12762 (15) 0.65511 (7) 0.0167 (4)
C5 0.2693 (3) 0.15291 (16) 0.67810 (7) 0.0199 (3)
H5 0.209888 0.228343 0.675178 0.024*
C6 0.1503 (3) 0.06836 (17) 0.70544 (8) 0.0202 (4)
H6 0.010827 0.085738 0.721251 0.024*
C7 0.6089 (3) 0.21588 (16) 0.62514 (8) 0.0203 (4)
H7A 0.762476 0.218253 0.639308 0.024*
H7B 0.616282 0.194859 0.587061 0.024*
C8 0.6281 (3) 0.41768 (16) 0.61422 (7) 0.0174 (4)
C9 0.4976 (3) 0.52931 (15) 0.62140 (7) 0.0160 (3)
H9 0.362205 0.523626 0.598465 0.019*
C10 0.8387 (3) 0.66093 (16) 0.62498 (7) 0.0171 (3)
H10 0.904670 0.609787 0.649839 0.021*
C11 0.6264 (3) 0.63434 (15) 0.60312 (7) 0.0156 (3)
C12 0.5334 (3) 0.70879 (15) 0.56694 (7) 0.0142 (3)
H12 0.392398 0.691113 0.552002 0.017*
C13 0.6437 (3) 0.81172 (15) 0.55137 (7) 0.0132 (3)
C14 0.8556 (3) 0.83769 (15) 0.57347 (6) 0.0133 (3)
C15 0.9494 (3) 0.75952 (15) 0.61064 (7) 0.0155 (3)
H15 1.090752 0.775661 0.625788 0.019*
C16 0.9659 (3) 0.94206 (15) 0.55873 (7) 0.0138 (3)
H16 1.106488 0.960738 0.573638 0.017*
C17 0.8666 (3) 1.01518 (15) 0.52280 (7) 0.0143 (3)
C18 0.6562 (3) 0.98877 (15) 0.50027 (7) 0.0152 (3)
H18 0.590593 1.039986 0.475384 0.018*
C19 0.5473 (3) 0.88988 (15) 0.51424 (7) 0.0142 (3)
H19 0.406282 0.873161 0.499054 0.017*
C20 1.1470 (3) 1.15938 (17) 0.53247 (8) 0.0209 (4)
H20A 1.189780 1.234095 0.517645 0.031*
H20B 1.269563 1.104703 0.527902 0.031*
H20C 1.113889 1.168001 0.570394 0.031*
C21 0.4167 (3) 0.54378 (16) 0.67891 (7) 0.0207 (4)
H21A 0.326793 0.477016 0.689058 0.031*
H21B 0.326442 0.613693 0.681681 0.031*
H21C 0.545311 0.549880 0.702678 0.031*
O1 0.5056 (2) 0.32711 (11) 0.63099 (5) 0.0200 (3)
O2 0.8126 (2) 0.40755 (12) 0.59612 (6) 0.0247 (3)
O3 0.9537 (2) 1.11748 (11) 0.50539 (5) 0.0187 (3)

1 Source of materials

The compound was obtained commercially (Bide Pharmatech Co., Ltd). Crystals suitable for the diffraction study were taken directly from the provided product.

2 Experimental details

Coordinates of hydrogen atoms were refined without any constraints or restraints. The U iso values were set to be 1.5U eq of the carrier atom for methyl H atoms and 1.2U eq for the remaining H atoms.

3 Comment

Naproxen, a potent non-steroidal anti-inflammatory drug (NSAID), blocks the activity of both COX-1 and COX-2 enzymes, which are key components of the cyclooxygenase pathway. Naproxen commonly causes gastrointestinal reactions, such as gastrointestinal bleeding. 1 These side effects may be linked to the carboxyl group present in naproxen. Esterifying the carboxyl group has been shown to reduce these side effects. Esterifying the carboxyl group has been shown to reduce these side effects. 2 , 3 Currently, naproxen is used clinically to treat or alleviate inflammation and pain caused by various conditions such as rheumatoid arthritis 4 and gout. 5 Additionally, naproxen has been found to exhibit anticancer activity against bladder 6 and prostate cancer. 7 Furthermore, studies have shown that naproxen acts against type A influenza viruses by binding to the viral nucleoprotein. 8 Therefore, the development of naproxen derivatives with fewer side effects is of significant importance.

The title compound contains one naphthyl ring and one phenyl ring. The bond distances of C–O are 1.372(2) Å (C17–O3), 1.433(2) Å (C20–O3), 1.353(2) Å (C8–O1), 1.442(2) Å (C7–O1) and 1.205(2) Å (C8–O2). The bond distance of C8–O2 are shorter than others, indicating a double bond. The bond of C–Br is 1.9057(19) Å (C1–Br1). The dihedral angels of ring 1 (C1–C2–C3–C4–C5–C6) and ring 2 (C10–C11–C12–C13–C14–C15), ring 1 (C1–C2–C3–C4–C5–C6) and ring 3 (C13–C14–C16–C17–C18–C19), and ring 2 (C10–C11–C12–C13–C14–C15) and ring 3 (C13–C14–C16–C17–C18–C19) are 56.58(5)°, 56.71(5)° and 0.78(5)°. The other bond distances and angles are in their normal ranges according to the previously reported compounds. 9 , 10 , 11 , 12


Corresponding author: Li-Na Gao, The Second Hospital of Jilin University, Changchun 130000, China; and School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China, E-mail:

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Competing interests: The authors declare no conflicts of interest regarding this article.

References

1. Bruker SAINT and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2000.Suche in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. Crystal Structure Refinement With SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

4. Huang, Z.; Vel’azquez, C. A.; Abdellatif, K. R. A.; Chowdhury, M. A.; Reisz, J. A.; DuMond, J. F.; King, S. B.; Knaus, E. E. Ethanesulfohydroxamic Acid Ester Prodrugs of Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Synthesis, Nitric Oxide and Nitroxyl Release, Cyclooxygenase Inhibition, Anti-Inflammatory, and Ulcerogenicity Index Studies. J. Med. Chem. 2011, 54, 1356–1364; https://doi.org/10.1021/jm101403g.Suche in Google Scholar PubMed

5. Han, M. I.; Kucukguzel, S. G. Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. Mini Rev. Med. Chem. 2020, 20, 1300–1310; https://doi.org/10.2174/1389557520666200505124922.Suche in Google Scholar PubMed

6. Srinivas, S.; Feldman, D. A Phase II Trial of Calcitriol and Naproxen in Recurrent Porstate Cancer. Anticancer Res. 2009, 29, 3605–3610.Suche in Google Scholar

7. Kim, M. S.; Kim, J. E.; Lim, D. Y.; Huang, Z.; Chen, H.; Langfald, A.; Lubet, R. A.; Grubbs, C. J.; Dong, Z.; Bode, A. M. Naproxen Induces Cell Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting P13–K. Cancer Prev. Res. 2014, 7, 236–245; https://doi.org/10.1158/1940-6207.capr-13-0288.Suche in Google Scholar

8. Wang, L. L.; Xue, D. D. Crystal Structure of 3-Phenylpropyl 2-(6-Methoxynaphthalen-2-yl)Propanoate, C23H24O3. Z. Kristallogr. N. Cryst. Struct. 2022, 237, 517–519; https://doi.org/10.1515/ncrs-2022-0114.Suche in Google Scholar

9. Liang, D.; Yang, X. H.; Sun, W.; Wang, W. N.; Yang, J. Z.; Liu, Y. Y.; Wang, G. S. Synthesis, Crystal Structure and Biological Activities of Naproxen-Eugenol Ester Progrug. Chem. Res. Chin. Univ. 2013, 29, 245–248; https://doi.org/10.1007/s40242-013-2266-9.Suche in Google Scholar

10. Li, F. R.; Zhang, Y. J.; Guo, F. G.; Duan, G. Y., Ge, Y. Q. 3-(4-Bromophenyl)-1-(4-Chlorobenzyl)-1H-Pyrazole-5-Carbaldehyde. Acta Crystallogr. 2012, E68, o2203.10.1107/S1600536812027298Suche in Google Scholar PubMed PubMed Central

11. Liu, Y.-L.; Zhang, H.-J.; Luo, J.; Chen, S.-X.; Zhang, J. Crystal Structure of Crystal Structure of N-(4-Bromobenzyl)-3-(Difluoromethyl)-1-Methyl-N-(Pyridin-2-yl)-1H-Pyrazole-4-Carboxamide, C18H15BrF2N4O.” Z. Kristallogr. N. Cryst. Struct. 2024, 239, 257–259. https://doi.org/10.1515/ncrs-2023-0513.Suche in Google Scholar

12. Jiang, J.; Jiang, H. Crystal Structure of (4-Bromobenzyl)Triphenylphosphonium Bromide Ethanol Solvate, C52H48Br4OP2. Z. Kristallogr. N. Cryst. Struct. 2024, 239 (3), 495–496. https://doi.org/10.1515/ncrs-2024-0060.Suche in Google Scholar

Received: 2024-07-08
Accepted: 2024-08-05
Published Online: 2024-09-02
Published in Print: 2024-12-17

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of 3-nitrophenol-2,1,3-benzoselenadiazole (1/1), C12H9N3O3Se
  4. Crystal structure of diaqua-(hydroxido)-{μ-[2-(hydroxy)-5-[(4-nitrophenyl)diazenyl]benzoato]}-{2-hydroxy-5-[(4-nitrophenyl)diazenyl]benzoato}-(1,10-phenanthroline)-diterbium hydrate, C38H27.4N8O12.2Tb
  5. Crystal structure of poly[bis(μ3-3-fluoro-4-(1H-1,2,4-triazol-1-yl)benzoato-κ3 O:O′:N)cadmium(II)] – dimethylformamide (1/1), C21H17CdF2N7O5
  6. The crystal structure of 2-amino-N-(pyridin-2-yl)benzamide, C12H11N3O
  7. The crystal structure of 2,3-di(pyridin-2-yl)-2,3-dihydroquinazolin-4(1H)-one, C18H14N4O
  8. Crystal structure of 2-chloro-4-fluorobenzyl (R)-2-(6-methoxynaphthalen-2-yl)propanoate, C21H18ClFO3
  9. Crystal structure of [1-(4-carboxyphenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylic acid]-(methylsulfinyl)methane, C15H16N2O6S
  10. The crystal structure of 2-ethyl-1,1-dimethyl-1H-benzo[e]indole, C16H17N
  11. The crystal structure of (Z)-5-amino-N -hydroxy-1H-pyrazole-4-carboximidamide, C4H7N5O
  12. The crystal structure of 2,2,5-trimethyl-3-(4-(4-(5-phenyl-4,5-dihydroisoxazol-3-yl)thiazol-2-yl)phenyl)imidazolidin-4-one, C24H24N4O2S
  13. The crystal structure of tetrakis(μ2-acetato-κ2 O:O′)-bis[(4′-phenyl-4,2′:6′,4″-terpyridine-κ1 N)dicopper(II)], C25H21CuN3O4
  14. Crystal structure of poly(3-thiophenecarboxylato-κ 3 O,O′:O′)-(methanol-κO)cadmium(II), C11H10O5S2Cd
  15. The crystal structure of dichloridobis[4′-(p-methoxylphenyl)-4,2′:6′,4″-terpyridine-κN] zinc(II), C44H34Cl2N6O2Zn
  16. The crystal structure of 1-(2-carboxyethyl)-1H-imidazole 3-oxide
  17. Crystal structure of 1,1′,1″-(nitrilotris(ethane-2,1-diyl))tris(3-(4-(((E)-pyridin-2-ylmethylene)amino)phenyl)urea), C45H47N13O4
  18. Crystal structure of a (E)-4-bromo-N-(4-(diethylamino)-2-hydroxybenzylidene) benzenaminium acetate ─ 4-bromoaniline (1/1)
  19. Crystal structure of 2,2′-(iminobis(methylene))bis(benzimidazolium) bis(p-toluenesulfonate), C30H31N5O6S2
  20. The crystal structure of alogliptinium meta-chlorobenzoate
  21. Crystal structure of 4-bromobenzyl 2-(6-methoxy-naphthalen-2-yl)propanoate, C21H19BrO3
  22. The hydrated double salt structure of (E)-4-(2-benzylidenehydrazine-1-carbonyl)pyridin-1-ium cation with 2-hydroxybenzoate and benzoate anions
  23. Crystal structure of (R)(R)-5-chloro-3-((S,1E,3E)-3,5-dimethyl-hepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate, C21H24ClNO4
  24. The crystal structure of bis(3-oxo-1,3-diphenylprop-1-en-1-olato-κ 2 O:O′)-bis(1,4-dioxane-κ 1 O)nickel(II), C38H38O8Ni
  25. Crystal structure of poly[aqua-(pyridine-3-carboxylato-κ1 N)(pyridine-3-carboxylato-κ2 O,O′) cadmium(II)] dihydrate, C12H14N2O7Cd
  26. The crystal structure of 4-(4-phenyl-5-(((1-(2,4,6-tribromophenyl)-1H-1,2,3-triazol-4-yl)methyl)thio)-4H-1,2,4-triazol-3-yl)pyridine, C22H14Br3N7S
  27. The crystal structure of N-benzylquinoline-2-carbothioamide, C17H14N2S
  28. Crystal structure of bis(3-isopropylphenyl)-4,4′-bipyridinium dichloride dihydrate, C28H30N2⋅2Cl⋅2H2O
  29. The crystal structure of ethyl 2-amino-4-(cyanophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C19H18N2O4
  30. Crystal structure of (4R,10S)-6-hydroxy-7-isopropyl-4,10-dimethyl-1,2,3,5-hexahydro-6,10-epoxyazulen-9-one, C15H22O3
  31. The crystal structure of (E)-(2-(2-hydroxy-3-methoxybenzylidene)aminophenyl)arsonic acid, C14H14AsNO5
  32. The crystal structure of poly[(μ 2-2-aminoisophthalato-κ4O,O′:O″:O″′)-(N-methylpyrrolidone κ1O)-dioxido-uranium(VI)], C13H14N2O7U
  33. The crystal structure of the co-crystal isonicotinamide · terephthalic acid, C8H6O4·2(C6H6N2O)
  34. The crystal structure of (E)-1-phenyl-3-(p-tolylthio)but-2-en-1-one, C17H16OS
  35. The crystal structure of 4,5-bis((Z)-chloro(hydroxyimino)methyl)-1H-imidazol-3-ium chloride monohydrate
  36. The crystal structure of 1,2-bis(4-(dimethylamino)phenyl)ethane-1,2-dione. C18H20N2O2
  37. Crystal structure of 2-chloro-4-fluorobenzyl 2-acetoxybenzoate, C16H12ClFO4
  38. Crystal structure of methyl 1-phenyl-9H-pyrido[3,4-b]indole-3-carboxylate, C19H14N2O2
  39. Crystal structure of (3-(dimethoxymethyl)-5-methoxy-1H-indol-1-yl)(5-fluoro-2-iodophenyl)methanone, C19H17FINO4
  40. Crystal structure of tetrachlorido-bis(1-[(1H-triazole-1-yl)methyl]-1H-benzotriazole-κ2 N:N′)dicopper, C36H32Cu2N24Cl4
  41. Crystal structure of 2-(2,3-bis(4-methoxyphenyl)-1H-pyrrolo[2,3-b]quinoxalin-1-yl)anilin, C30H24N4O2
  42. Crystal structure of 5,7-dihydroxy-2-phenyl-4H-chromen-4-one–N,N-dimethylformamide(1/1), C18H17NO5
  43. The crystal structure of bis(μ 2-biphenyl-2,2′-dicarboxylato)-diaqua-bis(nitrato)-bis(2,2′:6′,2′′-terpyridine)dineodymium(III), C46H32I2N8Nd2O16
  44. Crystal structure of (Z)-4-amino-N -((4-chlorophenyl)(phenyl)methylene)benzohydrazide, C20H16ClN3O
  45. Crystal structure of (E)-6,8-dimethoxy-4-(4-morpholinobenzylidene)-3,4-dihydro-1-benzoxepin-5(2H)-one, C23H25NO5
  46. Crystal structure of (R)-2-((3-(3-aminopiperidin-1-yl)-6-methyl-5-oxo-1,2,4-triazin-4(5H)-yl) methyl)-4-fluorobenzonitrile benzoate monohydrate, C24H27FN6O4
  47. The crystal structure of [triaqua-(8-carboxymethoxy-quinoline-2-carboxylato-κ 3 N,O,O)copper(II)]monohydrate, C12H15NO9Cu
  48. Crystal structure of (((4-chlorophenyl)sulfonyl)glycinato-κ 2 N,O)bis(1,10-phenanthroline-κ 2 N,N′)cobalt(II) tetrahydrate, C32H30ClCoN5O8S
  49. Crystal structure of (((3-nitrophenyl)sulfonyl)-β-alaninato-κO)bis(2,2′-bipyridine-κ 2 N, N′)copper(II) 3-nitrobenzenesulfonate, C35H29CuN7O11S2
  50. Crystal structure of 3-phenoxybenzyl 2-(6-methoxynaphthalen-2-yl)propanoate, C27H24O4
  51. 6-(2′,3′-Dihydroxy-3′-methylbutyl)-7-methoxy-8-(3″-methylbut-2″-en-1″-yl)-2H-chromen-2-one, C20H26O5
  52. Crystal structure of bromido-(2,2′:6′,2″-terpyridine-4′-onato-κ3N)palladium(II) methanol solvate
  53. The crystal structure of ethyl 2-amino-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carboxylate, C20H22N2O6
  54. Crystal structure of (1E,3E,5E)-1,6-bis(4-(pentyloxy)phenyl)hexa-1,3,5-triene, C28H36O2
  55. The crystal structure of tris(2-bromo-4-methylphenyl)amine, C21H18Br3N
  56. The crystal structure of 3-(2,5-dimethylanilino)-1-(2,5-dimethylphenyl)-4-methyl-1H-pyrrole-2,5-dione, C21H22N2O2
  57. Crystal structure of dicarbonyl (μ2-indole-2-carboxylato κ2 O:O′)tris(triphenylarsine-κAs)dirhodium(I) acetone solvate, C68H56As3NO5Rh2
  58. The crystal structure of 4-chloro-2-formylphenyl 4-methylbenzenesulfonate, C14H11ClO4S
  59. Crystal structure of 4-iodobenzyl 2-(6-methoxynaphthalen-2-yl) propanoate, C21H19IO3
Heruntergeladen am 6.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2024-0287/html
Button zum nach oben scrollen